## Approved for use through 07.013.001.001888 of 17.03 Approved for use through 07.013.001.001886 of 17.03 U.S. Patterni and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unusual studyous a valid DMS control rember. STATEMENT UNDER 37 CFR 3.73(b)

			vner: Alan Roberts					
App	olicatio	on No./Pat	ent No.: 10/644,530	)		Filed/Issue Date:	20 August 2003	
Application No./Patent No.: 10/644,530 Filed/Issue Date: 20 August 2003  Täled: Method for Increasing the Bioavailability of Glycopyrrolate								
Shionogl Inc. Corporation								
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency,							n, partnership, university, government agency, etc.	
states that it is:								
1.	$\boxtimes$	the assig	nee of the entire right	, litle, and interest i	in;			
2.		an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is						
3.	the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)							
the patent application/patent identified above, by virtue of either:								
A.		An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Real Frame , or for which a copy therefore is attached.						
OR	copy dieletore is attached.							
8.	X	A chain o	f title from the invento	r(s), of the patent a	pplication/p	atent identified abo	ove, to the current assignee as follows;	
		1. From:	Alan Roberts; Ba	laji Venkatarama	n		rizon Pharmaceutical Corporation	
			The document was re Reel 014458	corded in the Unit	ed States Pa 0484	stent and Tradema		
		2. From:	First Horizon Pha	rmaceutical Corp	oration	To: Sciele P	harma, Inc.	
			The document was re	corded in the Units	ed States Pa	itent and Tradema		
		3. From:	Sciele Pharma, In			To: Shionogi		
			The document was re Real 023979	corded in the Unite	ed States Pa	tent and Tradema		
[	X		i documents in the ch				threat a sopy thereof is stracting.	
X								
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]								
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee,								
	Sig	naktire	<u> </u>				17-Aeg-2011	
Greg Chopskie							Appelate Occurs Occurs	
Printed or Typed Name							Associate General Counsel Title	
This collection of information is required by 37 CFR 3,73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to								

Into Consociation in everywhere in requirement by 4 is 2 of 1 A (Sp.). The excentation is experience to collect or results a present on the late of the process) and speciation. Confidentiality in previouse) and speciation. Confidentiality in previouse of the provided by 3 of 15 (Co., 12 and 31 C (Feb. 11 and 11.4). This is an additional to each process and accordance to excentional to take 12 minutes to complete, including galibriting, preparing, and activation the provided application form to the USPTO. Time will vary depending upon the included to take 12 minutes to complete the previous of the provided process. The provided in the provided process of the provided process. The provided process of the provided process of the provided process. The provided process of the provided process. Use Provided process of the provided process. A provided provided process. Selbo To 15 (Seminalistic Collect, 13 of 13 A (Seminalistic Collect, 13 and 13

Supplemental Chain of Title Sheet

Applicant/Patent Owner: Alan Roberts et al.

Application No./Patent No.: 10/644,530 Filed/Issue Date: 20 August 2003

Titled: Method for Increasing the Bioavailability of Glycopyrrolate

4. From: Shìonogi Pharma, Inc. To: Shìonogi Inc.

The document was recorded in the United States Patent and Trademark Office at

Reel 026195, Frame 0403, or for which a copy thereof is attached.